Roger Chapman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1986927/publications.pdf

Version: 2024-02-01

		279487	360668
39	7,021	23	35
papers	citations	h-index	g-index
39	39	39	5815
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Provision and standards of care for treatment and follow-up of patients with auto-immune hepatitis (AIH). Frontline Gastroenterology, 2022, 13, flgastro-2021-101928.	0.9	O
2	Editorial: vancomycin – a promising option for the treatment of primary sclerosing cholangitis?. Alimentary Pharmacology and Therapeutics, 2018, 47, 1321-1322.	1.9	3
3	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	3.6	204
4	A rare cause of colonic thickening and lymphadenopathy. Gut, 2017, 66, 78-78.	6.1	0
5	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558.	1.8	202
6	Bile duct basement membrane thickening in primary sclerosing cholangitis. Histopathology, 2016, 68, 819-824.	1.6	9
7	Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2016, 44, 936-945.	1.9	27
8	Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. Quality of Life Research, 2016, 25, 947-957.	1.5	5
9	New Therapeutic Strategies for Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2016, 36, 005-014.	1.8	41
10	Editorial: further evidence for the role of serum alkaline phosphatase as a useful surrogate marker of prognosis in <scp>PSC</scp> . Alimentary Pharmacology and Therapeutics, 2015, 41, 149-151.	1.9	19
11	Response to Drs Shearer and Ford. American Journal of Gastroenterology, 2014, 109, 136.	0.2	O
12	Type 1 Autoimmune Pancreatitis and IgG4-Related Sclerosing Cholangitis Is Associated With Extrapancreatic Organ Failure, Malignancy, and Mortality in a Prospective UK Cohort. American Journal of Gastroenterology, 2014, 109, 1675-1683.	0.2	210
13	Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. Journal of Crohn's and Colitis, 2014, 8, 662-670.	0.6	45
14	Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2013, 108, 1508-1515.	0.2	133
15	PSC, AIH and overlap syndrome in inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 420-436.	0.7	47
16	OP07 Phenotypic description of a large cohort of PSC patients in the UK. Gut, 2011, 60, A53-A53.	6.1	0
17	Genomeâ€wide association studies in primary sclerosing cholangitis: Still more questions than answers?. Hepatology, 2011, 53, 2133-2135.	3.6	4
18	Diagnosis and management of primary sclerosing cholangitis. Hepatology, 2010, 51, 660-678.	3.6	1,048

#	Article	IF	CITATIONS
19	Chemoprevention and screening in primary sclerosing cholangitis. Postgraduate Medical Journal, 2008, 84, 228-237.	0.9	24
20	Etiopathogenesis of primary sclerosing cholangitis. World Journal of Gastroenterology, 2008, 14, 3350.	1.4	77
21	Review article: current management of primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2005, 21, 933-948.	1.9	71
22	Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid. Digestive and Liver Disease, 2003, 35, 306-308.	0.4	5
23	Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut, 2002, 51, 731-735.	6.1	184
24	To perform or not to perform liver biopsy-that is the question. Gut, 2002, 51, 9-10.	6.1	4
25	A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology, 2001, 121, 900-907.	0.6	330
26	Combination Therapy with Interferon-?? and Ribavirin for Hepatitis C. BioDrugs, 2001, 15, 225-238.	2.2	40
27	Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus. Journal of Experimental Medicine, 2000, 191, 1499-1512.	4.2	1,165
28	International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology, 1999, 31, 929-938.	1.8	2,681
29	Risk factors for biliary tract carcinogenesis. Annals of Oncology, 1999, 10 Suppl 4, 308-11.	0.6	67
30	The colon and PSC: new liver, new danger?. Gut, 1998, 43, 595-596.	6.1	15
31	Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. European Journal of Gastroenterology and Hepatology, 1997, 9, 575-580.	0.8	26
32	The enigma of anti-neutrophil antibodies in ulcerative colitis primary sclerosing cholangitis: Important genetic marker or epiphenomenon?. Hepatology, 1995, 21, 1473-1474.	3.6	7
33	Inappropriate expression of blood group antigens in hepatic allografts. Hepatology, 1994, 19, 876-881.	3.6	12
34	Raised gamma-glutamyltransferase activity and the need for liver biopsy BMJ: British Medical Journal, 1991, 302, 388-389.	2.4	17
35	Aetiology and natural history of primary sclerosing cholangitisa decade of progress?. Gut, 1991, 32, 1433-1435.	6.1	50
36	Role of Immune Factors in the Pathogenesis of Primary Sclerosing Cholangitis. Seminars in Liver Disease, 1991, 11, 1-4.	1.8	55

ROGER CHAPMAN

#	Article	IF	CITATIONS
37	The immunology of primary sclerosing cholangitis. Seminars in Immunopathology, 1990, 12, 121-8.	4.0	13
38	Liver transplantation for acute hepatic failure?. Lancet, The, 1990, 335, 32-35.	6.3	92
39	Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis Gut, 1988, 29, 422-427.	6.1	89